To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:5 Issue:5 Number:11 ISSN#:2564-2537
ACE Report #8938
Ace Report Cover Metabolic Disorders

WCO-IOF 2016: Alfacalcidol (Vit D analogue) vs. cholecalciferol (Vit D) for osteoporosis

How to Cite

OrthoEvidence. WCO-IOF 2016: Alfacalcidol (Vit D analogue) vs. cholecalciferol (Vit D) for osteoporosis. ACE Report. 2016;5(5):11. Available from:

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

The effect of alfacalcidol and plain vitamin D on osteoporosis: a randomized controlled trial

Contributing Authors:
BP Shrestha J Kathabania

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


80 patients with osteoporosis were randomized to receive either alfacalcidol, a vitamin D analogue, or plain vitamin D (cholecalciferol). Both treatment groups also received calcium supplementation and alendronate. The purpose of this study was to compare the effects on bone mineral density and T-score between alfacalcidol and cholecalciferol. Results demonstrated no significant differences betwee...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.